BioPharmSignal logoBioPharmSignal

Biotech News

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Therapeutics (TPST)Tempest TherapeuticsCompany update

Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development Tech transfer on track to support initiation of potentially registrational study in Q4 2026 Key manufacturing milestone follows

Open original release

Related news

TPSTTempest Therapeutics2026-05-14 20:15 EST

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

TPSTTempest Therapeutics2026-05-06 11:00 EST

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

LEGNLegend Biotech Corporation2026-06-15 12:00 EST

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

MGNXMacroGenics2026-05-11 21:20 EST

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

LEGNLegend Biotech Corporation2026-06-02 13:30 EST

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

FATEFate Therapeutics2026-05-21 12:30 EST

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

EXELExelixis2026-05-19 12:00 EST

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

View all latest news

Tempest Therapeutics

Tempest Therapeutics is an oncology company focused on small molecules and immunotherapy combinations for difficult cancers. Its investment case is driven by the idea that combination strategies can unlock differentiated responses in solid tumors.

Recent company news

TPSTTempest Therapeutics2026-05-29 12:00 EST

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

TPSTTempest Therapeutics2026-05-14 20:15 EST

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

TPSTTempest Therapeutics2026-05-06 11:00 EST

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

TPSTTempest Therapeutics2026-04-29 12:00 EST

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

TPSTTempest Therapeutics2026-04-22 12:00 EST

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Stock data

Close
0.93 USD
Market cap
19.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States